{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:30:19Z","timestamp":1787063419602,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T00:00:00Z","timestamp":1238716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p>\n                    <jats:bold>Background and purpose:\u2002<\/jats:bold>\n                    Bisphosphonates (BPs) are highly effective inhibitors of bone resorption. Nitrogen\u2010containing bisphosphonates (N\u2010BPs), such as zoledronic acid, induce the formation of a novel ATP analogue (1\u2010adenosin\u20105\u2032\u2010yl ester 3\u2010(3\u2010methylbut\u20103\u2010enyl) ester triphosphoric acid; ApppI), as a consequence of the inhibition of farnesyl pyrophosphate synthase and the accumulation of isopentenyl pyrophosphate (IPP). ApppI induces apoptosis, as do comparable metabolites of non\u2010nitrogen\u2010containing bisphosphonates (non\u2010N\u2010BPs). In order to further evaluate a pharmacological role for ApppI, we obtained more detailed data on IPP\/ApppI formation\n                    <jats:italic>in vivo<\/jats:italic>\n                    and\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Additionally, zoledronic acid\u2010induced ApppI formation from IPP was compared with the metabolism of clodronate (a non\u2010N\u2010BP) to adenosine 5\u2032(\u03b2,\u03b3\u2010dichloromethylene) triphosphate (AppCCl\n                    <jats:sub>2<\/jats:sub>\n                    p).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Experimental approach:\u2002<\/jats:bold>\n                    After giving zoledronic acid\n                    <jats:italic>in vivo<\/jats:italic>\n                    to rabbits, IPP\/ApppI formation and accumulation was assessed in isolated osteoclasts. The formation of ApppI from IPP was compared with the metabolism of clodronate in MCF\u20107 cells\n                    <jats:italic>in vitro<\/jats:italic>\n                    . IPP\/ApppI and AppCCl\n                    <jats:sub>2<\/jats:sub>\n                    p levels in cell extracts were analysed by mass spectrometry.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Key results:\u2002<\/jats:bold>\n                    Isopentenyl pyrophosphate\/ApppI were formed in osteoclasts\n                    <jats:italic>in vivo<\/jats:italic>\n                    , after a single, clinically relevant dose of zoledronic acid. Furthermore, exposure of MCF\u20107 cells\n                    <jats:italic>in vitro<\/jats:italic>\n                    to zoledronic acid at varying times and concentrations induced time\u2010 and dose\u2010dependent accumulation of IPP\/ApppI. One hour pulse treatment was sufficient to cause IPP accumulation and subsequent ApppI formation, or the metabolism of clodronate into AppCCl\n                    <jats:sub>2<\/jats:sub>\n                    p.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions and implications:\u2002<\/jats:bold>\n                    This study provided the first conclusive evidence that pro\u2010apoptotic ApppI is a biologically significant molecule, and demonstrated that IPP\/ApppI analysis is a sensitive tool for investigating pathways involved in BP action.\n                  <\/jats:p>","DOI":"10.1111\/j.1476-5381.2009.00160.x","type":"journal-article","created":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T12:56:23Z","timestamp":1238763383000},"page":"427-435","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Zoledronic acid induces formation of a pro\u2010apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts\n                    <i>in vivo<\/i>\n                    and in MCF\u20107 cells\n                    <i>in vitro<\/i>"],"prefix":"10.1111","volume":"157","author":[{"given":"Johanna","family":"R\u00e4ikk\u00f6nen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C","family":"Crockett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"M\u00f6nkk\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Auriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"M\u00f6nkk\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)41388-4"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(97)00490-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.1.131"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)42221-7"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2004.09.004"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.04.021"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk054"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08827-X"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060118"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm7015733"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)43091-3"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.68.1.157"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02555852"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.9.1358"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-60"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.61.5.1255"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1998.13.4.581"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(03)00039-3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706628"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2007.08.007"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3282f632bf"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1113"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <2961::AID-CNCR12>3.0.CO;2-L"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200500059"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958050-00005"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1402.089"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115539"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.1.88"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.07.007"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2009.00160.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2009.00160.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T19:56:22Z","timestamp":1697399782000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2009.00160.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,21]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1476-5381.2009.00160.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00160.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,21]]},"assertion":[{"value":"2009-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}